Evidence map›Paper›PMID 31221660›Full record

ArticleBlood advances2019

Tumor microenvironment and clonal monocytes from chronic myelomonocytic leukemia induce a procoagulant climate.

Johanna Zannoni, Natacha Mauz, Landry Seyve, Mathieu Meunier, Karin Pernet-Gallay, Julie Brault, Claire Jouzier, David Laurin, Mylène Pezet, Martine Pernollet and 4 more

Open access · goldAbstract readComparative Study
In one paragraph

Article in Blood advances, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Johanna ZannoniInstitute for Advanced Biosciences, INSERM U1209 and Centre National de la Recherche Scientifique Unité Mixte de Recherche (UMR) 5309, Grenoble Alpes University, Grenoble, France.
Natacha MauzInstitute for Advanced Biosciences, INSERM U1209 and Centre National de la Recherche Scientifique Unité Mixte de Recherche (UMR) 5309, Grenoble Alpes University, Grenoble, France.
Landry SeyveTechniques de l'Ingénierie Médicale et de la Complexité Informatique, Mathématiques et Applications-Thérapeutique Recombinante Expérimentale, UMR 5525 Centre National de la Recherche Scientifique, Grenoble Alpes University, Grenoble, France.
Mathieu MeunierInstitute for Advanced Biosciences, INSERM U1209 and Centre National de la Recherche Scientifique Unité Mixte de Recherche (UMR) 5309, Grenoble Alpes University, Grenoble, France.ORCID 0000-0002-1708-8606
Karin Pernet-GallayGrenoble Institute for Neurosciences, INSERM U1216, Plateforme de Microscopie Electronique, Grenoble, France.
Julie BraultTechniques de l'Ingénierie Médicale et de la Complexité Informatique, Mathématiques et Applications-Thérapeutique Recombinante Expérimentale, UMR 5525 Centre National de la Recherche Scientifique, Grenoble Alpes University, Grenoble, France.ORCID 0000-0002-1706-2158
Claire JouzierInstitute for Advanced Biosciences, INSERM U1209 and Centre National de la Recherche Scientifique Unité Mixte de Recherche (UMR) 5309, Grenoble Alpes University, Grenoble, France.
David LaurinInstitute for Advanced Biosciences, INSERM U1209 and Centre National de la Recherche Scientifique Unité Mixte de Recherche (UMR) 5309, Grenoble Alpes University, Grenoble, France.ORCID 0000-0001-9339-8369
Mylène PezetPlateforme de Microscopie Photonique, Cytométrie en Flux, Institute for Advanced Biosciences, Grenoble, France.ORCID 0000-0002-4365-7454
Martine PernolletInstitut de Biologie et de Pathologie, Laboratoire d'Immunologie, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France.
Jean-Yves CahnDepartment of Hematology, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France.ORCID 0000-0002-2356-7101
Fabrice CognasseEtablissement Français du Sang Rhône-Alpes-Auvergne, Saint-Etienne, France; and.ORCID 0000-0001-8041-928X
Benoît PolackTechniques de l'Ingénierie Médicale et de la Complexité Informatique, Mathématiques et Applications-Thérapeutique Recombinante Expérimentale, UMR 5525 Centre National de la Recherche Scientifique, Grenoble Alpes University, Grenoble, France.ORCID 0000-0002-1697-6249
Sophie ParkInstitute for Advanced Biosciences, INSERM U1209 and Centre National de la Recherche Scientifique Unité Mixte de Recherche (UMR) 5309, Grenoble Alpes University, Grenoble, France.ORCID 0000-0003-0514-5789
Centre National de la Recherche Scientifique · FRCentre Hospitalier Universitaire de Grenoble · FRÉtablissement Français du Sang · FRInserm · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic myelomonocytic leukemia (CMML) is a myeloid hematological malignancy with overlapping features of myelodysplastic syndromes (MDSs) and myeloproliferative neoplasms (MPNs). The knowledge of the role of the tumor microenvironment (TME), particularly mesenchymal stromal cells (MSCs), in MDS pathogenesis is increasing. Generally, cancer is associated with a procoagulant state participating in tumor development. Monocytes release procoagulant, tissue factor (TF)-bearing microparticles. We hypothesized that MSCs and clonal monocytes release procoagulant extracellular vesicles (EVs) within the CMML TME, inducing a procoagulant state that could modify hematopoietic stem cell (HSC) homeostasis. We isolated and cultured MSCs and monocytes from CMML patients and MSCs from healthy donors (HDs). Their medium EVs and small EVs (sEVs) were collected after iterative ultracentrifugations and characterized by nanoparticle tracking analysis. Their impact on hemostasis was studied with a thrombin generation assay and fibrinography. CMML or HD HSCs were exposed to sEVs from either CMML or HD MSCs. CMML MSC sEVs increased HD HSC procoagulant activity, suggesting a transfer of TF from the CMML TME to HD HSCs. The presence of TF on sEVs was shown by electron microscopy and western blot. Moreover, CMML monocyte EVs conferred a procoagulant activity to HD MSCs, which was reversed by an anti-TF antibody, suggesting the presence of TF on the EVs. Our findings revealed a procoagulant "climate" within the CMML environment related to TF-bearing sEVs secreted by CMML MSCs and monocytes.

Indexed as

Blood Coagulation FactorsCells, CulturedExtracellular VesiclesHematopoietic Stem CellsHomeostasisHumansLeukemia, Myelomonocytic, ChronicMesenchymal Stem CellsMonocytesNanoparticlesThromboplastinTumor MicroenvironmentBlood Coagulation Factorsleukocyte procoagulant activityThromboplastin

Identifiers

PMID31221660
PMCPMC6595258
OpenAlexW2951210548

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.